Tecan Academy launched in Europe
8 October 2013 | By Tecan
Tecan announces the European launch of its Tecan Academy web-based training tool...
List view / Grid view
News
Ben Venue Laboratories, Inc. to cease production
7 October 2013 | By Boehringer Ingelheim Corp
Ben Venue Laboratories, Inc has decided to cease production by the end of 2013...
MedImmune Completes Acquisition of Amplimmune
7 October 2013 | By AstraZeneca
As previously announced, the acquisition bolsters MedImmune’s oncology pipeline...
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
Intel and Janssen Pharmaceutica to collaborate with imec and 5 Flemish universities to open ExaScience Life Lab
7 October 2013 | By Mengele PMC
Lab will allow development of even more powerful supercomputers for life sciences research...
Janssen launches new initiative to drive health policy debate
7 October 2013 | By Publicis Life Brands Resolute
Multi-stakeholder collaboration at the heart of Janssen Health Policy Centre...
European health R&D investments stagnate for the first time in history Private industry invests 29 bln € in health R&D, and public authorities 18 bln €
7 October 2013 | By Publicis Life Brands Resolute
New report presents unique statistics on health R&D in the European Union...
The Nobel Prize in Physiology or Medicine 2013
7 October 2013 | By Nobel Prize
The 2013 Nobel Prize honours three scientists who have solved the mystery of how the cell organizes its transport system...
Novartis announces positive results from final Phase III omalizumab registration study in severe form of chronic skin disease CSU
5 October 2013 | By Novartis
"The positive new data clearly show the potential of omalizumab to treat CSU, a disease where more than 50% of patients don't respond..."
New data presented at 29th ECTRIMS Congress reinforce the clinical profile of investigational laquinimod on disease progression and inflammation in relapsing-remitting multiple sclerosis
4 October 2013 | By Teva Pharmaceutical Industries Ltd
Pooled data analysis of Phase III ALLEGRO and BRAVO studies add to our understanding of investigational laquinimod for relapsing-remitting Multiple Sclerosis...
New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients
4 October 2013 | By Novartis
"The data presented today are very encouraging because they are from studies that took place over four years..."
Regulatory update – GSK and Genmab announce European submission to regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
4 October 2013 | By GlaxoSmithKline
GlaxoSmithKline plc and Genmab announced the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra...
Amgen presents nearly two dozen abstracts from Romosozumab and Prolia® (Denosumab) at ASBMR
4 October 2013 | By Amgen
Prolia open-label extension trial showed continued increases in bone mineral density and low fracture incidence for up to eight years...
New Tecfidera® (Dimethyl Fumarate) data show stustained efficacy and long-term safety in a broad range of Multiple Sclerosis
4 October 2013 | By Biogen Idec
Interim results from ENDORSE extension study reinforce favorable safety profile in patients treated for up to six and a half years...
Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
3 October 2013 | By Sanofi
Data presented at ECTRIMS highlight potential of early intervention with Aubagio to delay second clinical attack and reduce MRI lesion burden...
